SG10202108306UA - G protein-coupled receptor (gpcr) modulation by imipridones - Google Patents

G protein-coupled receptor (gpcr) modulation by imipridones

Info

Publication number
SG10202108306UA
SG10202108306UA SG10202108306UA SG10202108306UA SG10202108306UA SG 10202108306U A SG10202108306U A SG 10202108306UA SG 10202108306U A SG10202108306U A SG 10202108306UA SG 10202108306U A SG10202108306U A SG 10202108306UA SG 10202108306U A SG10202108306U A SG 10202108306UA
Authority
SG
Singapore
Prior art keywords
imipridones
gpcr
modulation
protein
coupled receptor
Prior art date
Application number
SG10202108306UA
Inventor
Joshua E Allen
Martin Stogniew
Varun Vijay Prabhu
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/015817 external-priority patent/WO2016123571A1/en
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of SG10202108306UA publication Critical patent/SG10202108306UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
SG10202108306UA 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones SG10202108306UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
US201662308325P 2016-03-15 2016-03-15
US201662425403P 2016-11-22 2016-11-22

Publications (1)

Publication Number Publication Date
SG10202108306UA true SG10202108306UA (en) 2021-08-30

Family

ID=59398848

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202108306UA SG10202108306UA (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones
SG11201806401YA SG11201806401YA (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201806401YA SG11201806401YA (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Country Status (14)

Country Link
US (2) US11116771B2 (en)
EP (1) EP3408298A4 (en)
JP (2) JP7030701B2 (en)
KR (1) KR20180125460A (en)
CN (2) CN115844895A (en)
AU (2) AU2017211423B2 (en)
BR (1) BR112018015590A2 (en)
CA (1) CA3013044A1 (en)
IL (2) IL260815B (en)
MA (1) MA43879A (en)
MX (2) MX2018009227A (en)
NZ (1) NZ745425A (en)
SG (2) SG10202108306UA (en)
WO (1) WO2017132661A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US20210125683A1 (en) * 2017-09-15 2021-04-29 The Regents Of The University Of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
US11674963B2 (en) 2017-09-27 2023-06-13 The Regents Of The University Of California GPCRs in cancer-associated fibroblasts
CA3089864A1 (en) 2018-01-31 2019-08-08 Mayo Foundation For Medical Education And Research Methods of treating fibrotic pathologies
BR112020020831A2 (en) * 2018-04-09 2021-04-13 Orgenesis Inc. PARTICLES OF BIOXOMES, REDOXOMES, METHOD AND COMPOSITION
CN109157656B (en) * 2018-10-15 2021-08-27 重庆医科大学附属永川医院 Double-target tumor vaccine and preparation method and application thereof
KR102403686B1 (en) 2020-05-15 2022-05-31 뉴로핏 주식회사 Apparatus and method for providing posion of brain stimulation
JP2023536524A (en) 2020-08-06 2023-08-25 エトヴェシュ ロラーンド トゥドマニュジェテム Synthesis of novel imipridone derivatives and evaluation of their anticancer activity
CN112402439A (en) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 Application of miR-325 nucleic acid analogue in preparation of products related to improvement of liver collagen deposition
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
WO2024031030A2 (en) * 2022-08-03 2024-02-08 Shi Xiandong Quantitative method of determining a mental status based on drd1 and/or drd5, and its application thereof
CN115531378B (en) * 2022-10-19 2023-10-13 中国医学科学院医药生物技术研究所 Application of PHT427 as NDM-1 and KPC-2 dual inhibitor
CN116731136B (en) * 2023-08-04 2023-12-05 齐鲁工业大学(山东省科学院) Application of H3K23A histone point mutation in improving acetic acid tolerance and xylose fermentation performance of Saccharomyces cerevisiae

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (en) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo(1,2-a)pyrido(4,3-d)pyrimidines - withcns activity
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
CA2531571A1 (en) 2003-07-08 2005-01-27 The Regents Of The University Of California Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
WO2009039207A1 (en) 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
JP2014509323A (en) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ Treatment of cancer with dopamine receptor blockers
US8673923B2 (en) 2011-04-29 2014-03-18 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
CA2905037C (en) 2013-03-13 2023-08-29 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
MX2020002814A (en) * 2013-11-15 2022-02-15 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]p yrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use.
US10239877B2 (en) * 2014-03-31 2019-03-26 The Scripps Research Institute Pharmacophore for trail induction
KR102618971B1 (en) * 2015-01-30 2023-12-27 온코슈틱스 인코포레이티드 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 ( 1H)-one, its analogues, and salts thereof and methods of their use in treatment
CN104860948B (en) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 Imidazopyrimidine ketone compounds and its preparation method and application
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
US11116771B2 (en) 2021-09-14
MX2018009227A (en) 2018-11-09
EP3408298A4 (en) 2019-09-04
CN109311980B (en) 2023-01-17
AU2017211423B2 (en) 2021-10-28
WO2017132661A2 (en) 2017-08-03
MX2023004443A (en) 2023-05-08
IL260815B (en) 2021-10-31
US20190307751A1 (en) 2019-10-10
CN109311980A (en) 2019-02-05
WO2017132661A3 (en) 2017-08-31
AU2022200583B2 (en) 2024-05-02
AU2022200583A1 (en) 2022-02-24
CN115844895A (en) 2023-03-28
JP2022046528A (en) 2022-03-23
CA3013044A1 (en) 2017-08-03
AU2017211423A1 (en) 2018-09-06
MA43879A (en) 2018-12-05
EP3408298A2 (en) 2018-12-05
IL286923A (en) 2021-10-31
JP2019511460A (en) 2019-04-25
BR112018015590A2 (en) 2019-10-01
NZ745425A (en) 2023-03-31
KR20180125460A (en) 2018-11-23
SG11201806401YA (en) 2018-08-30
US20220072001A1 (en) 2022-03-10
JP7030701B2 (en) 2022-03-07

Similar Documents

Publication Publication Date Title
IL286923A (en) G protein-coupled receptor (gpcr) modulation by imipridones
IL285318A (en) Estrogen receptor modulators
HK1252163A1 (en) Receptor
GB201514875D0 (en) Receptor
ZA201700342B (en) Novel glp-1 receptor modulators
HRP20190024T1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
IL268263A (en) Estrogen receptor modulators
GB201702617D0 (en) Receptor
EP3350167A4 (en) Androgen receptor antagonists
PT3169452T (en) Adjustment mechanism for grading systems
IL249160A0 (en) Crystalline forms of an estrogen receptor modulator
EP3865472C0 (en) Thromboxane receptor antagonists
IL252565B (en) Novel glp-1 receptor modulators
EP3224230A4 (en) Estrogen receptor modulators
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
GB201616065D0 (en) Receptor modulator compounds
GB201616071D0 (en) Receptor modulator compounds
GB201616072D0 (en) Receptor modulator compounds
GB201603861D0 (en) Receptor modulation
GB201512714D0 (en) Receptor modulator compounds
GB201504285D0 (en) Receptor modulation